NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44-Clinical Trial Required)

Key Facts

Status: Forecasted

Posted date: December 1, 2023

Archive date: February 12, 2027

Close date: January 7, 2027

Opportunity ID: 351266

Opportunity number: PAR-24-066

Opportunity category: Discretionary

Agency name: National Institutes of Health

Agency code: HHS-NIH11

Award floor: $0

Award ceiling: $0

Cost sharing required: No

Funding Instrument Types
  • Cooperative Agreement
Category of Funding Activity
  • Health
Eligible Applicants
  • Small businesses
Tools
Categories (use these for quoted searches)
  • agency_code:hhs_nih11
  • category_of_funding_activity:health
  • cost_sharing_or_matching_requirement:false
  • eligible_applicants:small_businesses
  • funding_instrument_type:cooperative_agreement
  • opportunity_category:discretionary
  • status:forecasted
Description

The NEI uses this U44 Notice of Funding Opportunity to support SBIR grant applications from small business concerns (SBCs) that propose to implement investigator-initiated, early-stage clinical trials with greater than minimal risk and typically are Phase I or II trials. The risk level of the U44 trial requires appropriate performance oversight and safety monitoring. For purposes of this NOFO, the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.

NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44-Clinical Trial Required)
The NEI uses this U44 Notice of Funding Opportunity to support SBIR grant applications from small business concerns (SBCs) that propose to implement investigator-initiated, early-stage clinical trials with greater than minimal risk and typically are Phase I or II trials. The risk level of the U44 trial requires appropriate performance oversight and safety monitoring. For purposes of this NOFO, the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.
[Forecasted] NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44-Clinical Trial Required)
Forecasted
National Institutes of Health
Health
Cooperative Agreement
Small businesses
2023-12-01